Medicare AdvantagePrior AuthMedium impact
Ibtrozi (taletrectinib) (Revised)
Humana·Oncology, Pulmonology·Medicare Advantage
Effective date
Aug 27, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Ibtrozi (taletrectinib), a new oral cancer medication for ROS1-positive non-small cell lung cancer. Coverage requires meeting three specific criteria including confirmed ROS1-positive NSCLC diagnosis and monotherapy use.
Action Required
By August 27, 2025: Billing team must update prior authorization workflow for Ibtrozi (taletrectinib) prescriptions for Medicare Advantage patients. Providers must verify patient meets all three criteria: locally advanced/metastatic NSCLC diagnosis, ROS1-positive disease, and monotherapy use. Submit prior auth requests through www.humana.com/PAL before prescribing. Claims will be denied without prior authorization.